Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of Cambrex (NYSE:CBM), a life sciences company that provides active pharmaceutical ingredients and pharmaceutical intermediates to branded and generic drug developers, sank as much as 19% after the company reported fourth-quarter results and announced its full-year 2014 guidance.
So what: According to Cambrex's report, revenue increase 46.3% during the quarter to $103 million, while fourth-quarter EBITDA jumped to $22.2 million and adjusted earnings per share came in at $0.30 compared to a one-time tax benefit removed $0.22 last year. Both figures actually surpassed Wall Street's expectations for just $0.29 in EPS on $93.8 million in revenue. Cambrex's report notes strong branded active pharmaceutical ingredient sales offset by weaker sales of generic APIs. Looking at 2014, however, is where the wheels went flat. Cambrex forecasts EPS of $0.99-$1.10 on sales growth of 8%-12%, suggesting $340 million-$352 million in revenue. While the revenue figure meets the Street's forecast, the midpoint of EPS is modestly below the current consensus of $1.11.
Now what: Cambrex has had an incredible run over the past couple of weeks, so today's throttling seems fitting since its guidance simply didn't meet lofty shareholder expectations. However, I would certainly consider a decent pullback in this stock as grounds to give it a deeper look. It's clear that Cambrex's API portfolio is expanding and its top line is certainly capable of roughly 10% growth per year. This means plenty of growth potential for investors if Cambrex's share price continues to fall.
Cambrex may have risen significantly to start the year, but it'll likely have a hard time keeping up with this top stock in 2014
There's a huge difference between a good stock and a stock that can make you rich. The Motley Fool's chief investment officer has selected his No. 1 stock for 2014, and it's one of those stocks that could make you rich. You can find out which stock it is in the special free report "The Motley Fool's Top Stock for 2014." Just click here to access the report and find out the name of this under-the-radar company.
Sean Williams has no material interest in any companies mentioned in this article. You can follow him on CAPS under the screen name TMFUltraLong, track every pick he makes under the screen name TrackUltraLong, and check him out on Twitter, where he goes by the handle @TMFUltraLong.
The Motley Fool has no position in any companies mentioned in this article. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.